Previous 10 | Next 10 |
Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference...
Inhibikase Therapeutics Highlights 2022 Pipeline Goals and Milestones PR Newswire BOSTON and ATLANTA , Jan. 5, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics ...
Krystal Biotech KRYS +115% says study on VYJUVEKTM for rare skin disease met primary endpoint Petros Pharmaceuticals PTPI +62% 180 Life Sciences, Vaxart gain amid social media buzz; Petros climb over 60% NRx Pharmaceuticals NRXP +48% after Zyesami increased likel...
Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease - Publication describes role of c-Abl and misfolded alpha-synuclein proteins in the initiation and pr...
Inhibikase Therapeutics (NASDAQ:IKT): Q3 GAAP EPS of -$0.18. Revenue of $0.33M (+725.0% Y/Y) Press Release For further details see: Inhibikase Therapeutics reports Q3 results
Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity PR Newswire BOSTON and ATLANTA , Nov. 15, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceut...
Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit PR Newswire ATLANTA and BOSTON , Oct. 27, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical compan...
Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009 PR Newswire ATLANTA , Oct. 19, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical c...
Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease - Interim animal data indicate toxicology profile improves with extended daily oral d...
Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy PR Newswire ATLANTA , Sept. 23, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "C...
News, Short Squeeze, Breakout and More Instantly...
Inhibikase Therapeutics Inc. Company Name:
IKT Stock Symbol:
NASDAQ Market:
Inhibikase Therapeutics Inc. Website:
BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...
- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kin...
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson...